REPH - REPH STOCK NEWS

Recro Pharma (NASDAQ: REPH) announced a new development and cGMP manufacturing agreement with an unspecified client. This contract focuses on early-stage development capabilities for an oral, minimally-absorbed investigational compound. President David Enloe emphasized Recro's expertise in complex formulation challenges, underlining the growth potential of this partnership. The company operates from a 120,000 square-foot facility in Gainesville, Georgia, offering extensive CDMO services, including clinical and commercial manufacturing.

Recro Pharma, Inc. (NASDAQ: REPH) announced the hiring of new employees to bolster business development and technical operations. To incentivize these hires, the company granted inducement stock options for 91,830 shares and restricted stock units for 15,000 shares, effective June 30, 2021. These awards will vest over four years, aligning employee interests with company performance. Recro specializes in contract development and manufacturing services for oral solid dosage forms, aiming to address complex formulation challenges in pharmaceuticals.

Recro Pharma (NASDAQ: REPH) has appointed Dr. Laura L. Parks to its board of directors. Dr. Parks brings over three decades of experience in the biopharma and CDMO sectors, having held key roles at Patheon and DSM Pharmaceuticals. She is expected to enhance Recro's strategic commercial and operational initiatives as the company aims to expand its client base. Recro focuses on solving complex challenges for oral solid dose drug products and is positioned to benefit from the growing demand for domestic CDMO services.

Recro Pharma (NASDAQ: REPH) has expanded its Clinical Trial Services (CTS) by adding clinical-scale sachet and blister packaging. A successful audit by a European Union Qualified Person (QP) verified that Recro complies with necessary GMP manufacturing standards. This positions Recro to support European clinical trial efforts, enhancing business prospects amid growing demand.

Recro Pharma (NASDAQ: REPH) announced a new development agreement with Astex Pharmaceuticals, a leader in cancer therapeutics. This partnership reinforces Recro's commitment to building strong relationships with CDMO customers. Recro specializes in complex formulation and manufacturing for oral solid dose products, offering services from early feasibility to commercial manufacturing. Their facilities span 120,000 square feet in Gainesville, Georgia, supporting a wide range of pharmaceutical development needs.

Recro Pharma, Inc. (NASD:REPH) has completed its underwritten public offering of 15,333,332 shares, raising approximately $34.5 million, including $2.25 per share from the full exercise of underwriters’ options.

The funds will primarily support general corporate purposes, including potential debt repayment and future acquisitions, though no specific deals are currently in place. William Blair & Company served as the sole book-running manager.

Recro Pharma (REPH) has announced pricing for its public offering of 13,333,333 shares at $2.25 each, aiming to raise approximately $30 million before expenses. The offering will close around May 14, 2021, pending standard closing conditions. Proceeds are intended for general corporate purposes, including debt repayment and potential acquisitions, though no immediate acquisitions are planned. William Blair & Company acts as the sole manager for the offering, with an option for underwriters to purchase an additional 1,999,999 shares.

Recro Pharma (NASDAQ: REPH) announced its intention to conduct an underwritten public offering of common stock, subject to market conditions. The offering will allow Recro to raise capital, with the potential to grant underwriters an option to purchase an additional 15% of the shares. Proceeds from the offering will be used for general corporate purposes, including debt repayment and potential acquisitions, although no immediate plans for acquisitions are disclosed. The offering will be executed under a shelf registration statement effective since March 2019.